Medicare Compliance & Reimbursement

Hint: Get ready for ‘Comirnaty.’

Even though your practice may already be fielding COVID-19 vaccine questions left and right, get ready to be bombarded with more inquiries.

Why? On Aug. 23, the Food and Drug Administration’s (FDA’s) moved the Pfizer-BioNTech COVID-19 Vaccine from its emergency use authorization (EUA) status to fully approved for individuals 16 and up. The vaccine is rebranded under a new name, “Comirnaty,” which may confuse consumers.

But: The Pfizer vaccine will retain its EUA status for “individuals 12 through 15 years of age and for the administration of a third dose in certain immunocompromised individuals,” an FDA release said.

“While millions of people have already safely received COVID-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated. said Acting FDA Commissioner Janet Woodcock, MD, in a release on the change.

The FDA, in coordination with the Centers for Disease Control and Prevention (CDC) plans to continue its extensive safety monitoring of the Comirnaty COVID-19 Vaccine, but assures the “public and medical community [they] can be confident that although we approved this vaccine expeditiously, it was fully in keeping with our existing high standards for vaccines in the U.S,” indicated Peter Marks, MD, PhD, director of FDA’s Center for Biologics Evaluation and Research, in the FDA release.

Resource: See the timeline and find more information on the Comirnaty COVID-19 Vaccine at www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine.